Blog
RSS FeedPosted by Michael Wonder on 12 Sep 2016
Blood cancer drug approved for use on Scottish NHS
12 September 2016 - Scottish patients with a rare form of blood cancer have been granted access to a daily pill ...
Posted by Michael Wonder on 12 Sep 2016
SMC - September 2016 decisions
12 September 2016 - Three new medicines accepted for routine use by NHS Scotland. ...
Posted by Michael Wonder on 09 Sep 2016
More options to be made available to treat hepatitis C
9 September 2016 - Another ‘potential curative’ drug for people with chronic hepatitis C will be made available on the NHS. ...
Posted by Michael Wonder on 08 Sep 2016
Coil is more effective than pill as emergency contraception, says NICE
8 September 2016 - NICE is calling for women to be told that the coil is more effective than the ‘morning ...
Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable. ...
Posted by Michael Wonder on 07 Sep 2016
Generic drug approvals since the 1984 Hatch-Waxman Act
6 September 2016 - This study, published in JAMA, uses US FDA data to identify approved generic drugs manufactured between September ...
Posted by Michael Wonder on 06 Sep 2016
European Commission approves Bristol-Myers Squibb’s Orencia (abatacept) for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate
6 September 2016 - Bristol-Myers Squibb Company today announced that the European Commission has approved Orencia (abatacept) intravenous infusion and subcutaneous ...
Posted by Michael Wonder on 06 Sep 2016
NICE rejects Roche’s melanoma combination
6 September 2016 - Patients in England and Wales with melanoma will not be getting routine access to Roche's Cotellic/Zelboraf combination ...
Posted by Michael Wonder on 05 Sep 2016
EMA publishes EPAR for Zalmoxis
5 September 2016 - The EMA has published an EPAR for GSK's new cellular therapy Zalmoxis. ...
Posted by Michael Wonder on 05 Sep 2016
Xultophy (insulin degludec/liraglutide) receives European approval for use in adults with type 2 diabetes mellitus and moderate renal impairment
1 September 2016 - Novo Nordisk has announced that the European Commission has approved the expanded use of Xultophy (insulin degludec ...
Posted by Michael Wonder on 05 Sep 2016
TGA approves new indication for Gazyva
5 September 2016 - The TGA has approved a new use for Roche's CD20 receptor antagonist. ...
Posted by Michael Wonder on 05 Sep 2016
Eisai bewildered as Germany's IQWIG fails to recognise additional benefit of Halaven (eribulin mesylate) in the treatment of advanced liposarcoma
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...
Posted by Michael Wonder on 05 Sep 2016
EMA publishes EPAR for Aerivio Spiromax
5 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' version of GSK's Seretide/Advair. ...
Posted by Michael Wonder on 03 Sep 2016
FDA allows marketing of clot retrieval devices to reduce disability in stroke patients
2 September 2016 - The U.S. FDA today allowed marketing of two Trevo clot retrieval devices as an initial therapy for ...
Posted by Michael Wonder on 03 Sep 2016
NICE recommends Cancer Drugs Fund treatment for prostate cancer for routine NHS use
2 September 2016 - More prostate cancer patients will receive radium 223 after NICE approved it for routine NHS use. ...